Kentucky Retirement Systems grew its position in Abbott Laboratories (NYSE:ABT – Free Report) by 17.4% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 127,655 shares of the healthcare product maker’s stock after purchasing an additional 18,937 shares during the quarter. Kentucky Retirement Systems’ holdings in Abbott Laboratories were worth $13,106,000 at the end of the most recent reporting period.
A number of other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares in the last quarter. United Bank raised its stake in Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after acquiring an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC lifted its holdings in shares of Abbott Laboratories by 13.6% in the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after acquiring an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board grew its holdings in shares of Abbott Laboratories by 25.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after purchasing an additional 292,547 shares during the last quarter. 75.18% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of analysts have weighed in on the stock. Leerink Partners cut their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Robert W. Baird started coverage on Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective on the stock. UBS Group lowered their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday. The Goldman Sachs Group dropped their target price on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Finally, Bank of America reduced their price target on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $118.17.
Abbott Laboratories Trading Up 0.8%
NYSE ABT opened at $108.15 on Thursday. The firm has a market capitalization of $188.38 billion, a PE ratio of 35.00, a price-to-earnings-growth ratio of 2.08 and a beta of 0.61. The business’s 50-day moving average price is $92.72 and its two-hundred day moving average price is $100.73. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49.
Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The firm’s revenue was up 13.0% compared to the same quarter last year. During the same period last year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.
Abbott Laboratories Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is 81.55%.
Key Stories Impacting Abbott Laboratories
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: UBS reaffirmed a Buy rating on Abbott, supporting the view that the recent pullback has created an attractive entry point. UBS Issues a Buy Rating on Abbott Laboratories
- Positive Sentiment: TD Cowen maintained its Buy rating and set a $115 price target, citing a strengthening nutrition franchise and 2026 growth opportunities. Abbott Laboratories Buy Rating Backed by Growth Drivers
- Positive Sentiment: Recent quarterly results exceeded expectations, with earnings and revenue above consensus and year-over-year revenue growth of 13%. Coverage also highlights record results and raised outlooks during the current earnings season. Companies Reported Record Results and Raised Guidance
- Positive Sentiment: Analysts continue to see long-term expansion in diabetes care, oncology diagnostics and heart-care devices, while Erste Group slightly raised its 2027 EPS forecast to $6.06 from $6.05. Abbott Growth Trends
- Neutral Sentiment: Abbott began a roughly 1,000-patient real-world study of its TriClip heart-valve repair system. The study could strengthen adoption, but it also underscores rising competition from Edwards Lifesciences. Abbott Starts TriClip Study
- Neutral Sentiment: A personal-finance article included Abbott among dividend stocks suitable for long-term passive income, but it offered limited new company-specific information. Dividend Stocks for Passive Income
- Negative Sentiment: UBS lowered its price target from $135 to $125 while retaining a Buy rating, signaling somewhat less near-term upside despite continued confidence in Abbott’s fundamentals.
Abbott Laboratories Profile
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
